Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23934694 | 0.87 | KDM4E (0.30) | ALOX15KDM4E | |
| SCHEMBL23739497 | 0.86 | THRB (0.33) | ALOX15KDM4EMAPTALDH1A1POLB | |
| SCHEMBL18639836 | 0.86 | KDM4E (0.39) | ALOX15KDM4EMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL18639839 | 0.86 | KDM4E (0.39) | ALOX15KDM4EMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL18639818 | 0.86 | KDM4E (0.39) | ALOX15KDM4EMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL21848620 | 0.84 | THRB (0.34) | ALOX15KDM4EMAPTALDH1A1POLB | |
| SCHEMBL23739760 | 0.82 | ALOX15 (0.34) | ALOX15KDM4EMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL18639837 | 0.82 | NPC1 (0.33) | ALOX15KDM4EALDH1A1POLB | |
| SCHEMBL18639867 | 0.82 | NPC1 (0.33) | ALOX15KDM4EALDH1A1POLB | |
| SCHEMBL18666828 | 0.82 | NPC1 (0.33) | ALOX15KDM4EALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159559-A1 | COMPOUND FOR INHIBITING AND INDUCING DEGRADATION OF EGFR KINASE | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159559-A1 | COMPOUND FOR INHIBITING AND INDUCING DEGRADATION OF EGFR KINASE | EGFR, ERBB2, ERBB3 | ALOX15 3452/4885KDM4E 2220/4885MAPT 2433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.